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vs. 62%) and have rheumatoid arthritis (62% vs. 43%), 1 or 2 comorbidities (70% vs. 
42%), poorer health status (mean GSRH score, 46 vs 55), on long-term disability 
(13% vs. 2%), and discussed more biologic treatment options (mean number, 3 vs 
2) than non-SDM respondents. Non-SDM respondents were more likely to have 
psoriasis (25% vs. 8%) and no comorbidities (48% vs. 23%) than SDM respondents 
(p< 0.05 for all comparisons). CONCLUSIONS: The preliminary results suggest that 
patients who participate in SDM for biologic therapy initiation differ clinically and 
demographically in comparison to those who do not, however these findings need 
to be confirmed in the final study data.
PSY56
SYStematic review of the PatternS of uSe, characteriSticS, and 
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OBJECTIVES: A number of new therapeutics are moving into phase 2 clinical tri-
als for treatment of celiac disease (CD), a condition with no treatment other than 
gluten-free diet. Owing to the nature of CD, these trials will require a meaningful and 
validated patient-reported outcome measure (PROM) to quantify the symptomatic 
improvement of patients. The aim of this systematic review is to evaluate PROs for 
suitability in an FDA approval trial for a CD therapeutic. METHODS: A systematic 
search was performed in 5 online databases (MedLine, EmBase, Web of Science, 
CENTRAL, CINAHL) for studies that enrolled patients with CD and used a PROM 
Instruments included inthis review had to measure some PRO concept, be patient 
administered and based upon a previously validated instrument. RESULTS: Our 
literature search identified 2702 unique records of which 157 ultimately qualified 
for abstraction. The majority of studies identified were performed in adults (77%), 
had a cross-sectional design (69%) and were of moderate size (average n= 402). The 
most commonly used PROMs were the SF36, Gastrointestinal Symptom Rating Scale 
(GSRS) and Psychological General Well-Being Measure (PGWB). Only 11% of studies 
identified had a randomized design. Although PROMs specific to CD were identi-
fied they were used only in 10% of studies. CONCLUSIONS: A large literature exists 
of the measurement of QoL in CD patients but PRO instruments used previously 
have been generic health-related QoL instruments unrelated to the specific set of 
symptoms that characterizes CD. Given the limited number of randomized trials in 
CD it is unclear how any of these instruments will perform in the context of trials 
aiming at FDA approval. Better identification of CD-specific concepts and evidence 
of good instrument performance are necessary before a PRO can be relied upon as 
an efficacy measure in CD.
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OBJECTIVES: To identify patient-reported outcome (PRO) measures which were 
used in patients with type 1 myotonic dystrophy (DM1) and to examine the dis-
ease burden on function and health-related quality of life (HRQoL). METHODS: A 
systematic literature review was conducted through PubMed and MEDLINE for PRO 
measures in DM1 as of July 19, 2014. Search keywords were: myotonic dystrophy, 
patient-reported outcome, patient satisfaction, patient preference, patient rating, 
quality of life, and HRQoL. English language articles published between 2000 and 
July 2014 were reviewed. We examined the PRO burden in DM1 patients, with a 
focus on longitudinal studies. In addition, we searched for additional PRO measures 
through clinical trial databases including clinicaltrials.gov and clinicaltrialsregister.
eu. RESULTS: A total of 118 studies were identified in the initial literature search. 
After further review, we found 20 PRO measures in 21 prior studies. In addition, 
we identified two other PRO measures through clinical trial databases. Most of 
the 22 PRO measures identified were generic and covered one or two functional 
or HRQoL domains. The Myotonic Dystrophy Health Index (MDHI) is the only PRO 
measure that was specifically developed for DM1. Based on the literature, DM1 
patients experienced impairment in several domains, including pain, fatigue, and 
sleep disturbances. Only three longitudinal studies were identified and they all indi-
cated significant deterioration in the HRQoL in DM1 patients over time; marked with 
decreased ambulation and increased dependence on others. CONCLUSIONS: There 
are a limited number of studies examining PROs in patients with DM1, which repre-
sents a missed opportunity to understand this complex disease from the patients’ 
perspective. More validation work is needed for existing PRO measures in the DM1 
population to allow use in future drug development. In addition, our study high-
lights the high unmet need for an effective treatment, as prior studies consistently 
reported a substantial PRO burden for DM1.
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OBJECTIVES: Hemophilia A and B are marked by frequent joint bleeding, result-
ing in pain and functional impairment. This study aimed to assess the reliability 
of five PRO instruments in PWH in a non-bleeding state. METHODS: Sequential 
adult male PWH of any severity (with or without inhibitors) with a history of joint 
a change of ≥ 5 points on the FACT-Lym, with 57 of the 80 “responders” who had a 
post-baseline FACT-Lym evaluation (71.3%) achieving this clinically-meaningful level 
of improved quality of life. CONCLUSIONS: Single-agent ibrutinib was highly effica-
cious in this study with a majority of patients responding to therapy and achieving 
long, durable remissions. Moreover, patients with clinical responses to ibrutinib also 
tended to show clinically-meaningful improvements in patient-reported outcomes.
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OBJECTIVES: Psychosocial and environmental factors might have a potential causal 
relationship with chronic pain and the related disability. Psychosocial and environ-
mental factors, socioeconomic status (SES) mediate the relationship among pain, 
disability, and can cause the morbidity and mortality among various conditions. 
Factor analyses of the Pain catastrophizing Scale (PCS) have shown that catastro-
phizing can be viewed as a multidimensional construct comprising elements of 
rumination, magnification and helplessness. The purpose of this study was to 
investigate the correlation between catastrophizing and the level of pain intensity, 
disability, in patients with chronic low back pain (CLBP). METHODS: An observa-
tional study was conducted. Participants were recruited from pain clinic of a public 
tertiary care hospital. Patients of either gender, aged 18–75 years with CLBP for ≥ 
3 months, were eligible for study. Data regarding pain intensity, disability using 
MODQ (Modified Oswestry Disability Questionnaire), coping behaviour using PCS, 
socioeconomic status using Kuppuswamy scale, demographic and disease details 
were collected. Multiple correlation analysis was performed among the clinical 
variables with level of significance of 0.05. RESULTS: A total of 74 patients were 
included in the study. Mean age and duration of low back pain was 46±14 yrs and 
36±32 months respectively. The mean helplessness, magnification and rumination 
were found 11.7±3, 5.5±2 and 7.3±2 respectively. We found a signification positive 
correlation between total PCS and pain intensity (r = 0.66, P = 0.001), disability (r = 
0.67, P = 0.001). Socioeconomic status (r = 0.15, P = 0.09) and duration of low back 
pain (r = 0.06, P = 0.3) was not significantly correlated with total PCS score. A similar 
trend was seen among the subscales of PCS. CONCLUSIONS: Coping behaviours in 
patients was significantly negatively associated with pain intensity and disability. 
Treatment aimed at reducing pain intensity and disability can improve patients 
coping behaviour.
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a review of Patient-rePorted outcomeS (ProS) in PatientS with 
cutaneouS luPuS erYthematoSuS (cle)
Ogunsanya M.1, Kalb S.2, Chen S.2
1The University of Texas at Austin, Austin, TX, USA, 2Biogen Idec, Cambridge, MA, USA
OBJECTIVES: To identify patient-reported outcome (PRO) instruments used in 
patients with cutaneous lupus erythematosus (CLE). METHODS: A literature search 
was conducted to identify PROs used in CLE patients. We searched PubMed, and 
Web of Science/MEDLINE databases to identify studies using “CLE/cutaneous lupus 
erythematosus,” in combination with PRO-related keywords such as “quality of 
life,” “self-report,” and “instrument.” English language articles published between 
2003 and 2014 were identified. RESULTS: A total of 482 citations were identified in 
the initial search of the journal databases. A total of 305 abstracts were excluded 
as the studies were not conducted in CLE patients, or did not use PRO instruments. 
After reviewing the remaining 177 abstracts in detail, 12 studies were included 
in the final summary review. Aside from generic instruments, potential disease 
related instruments that have been used in CLE patients include Skindex (16 and 29 
items), Dermatology Life Quality Index (DLQI), Body Image Quality of Life Inventory 
(BIQLI), and global assessments of pain and pruritus using Visual Analog Scales 
(VAS). CONCLUSIONS: There is a limited number of studies examining PRO in 
patients with CLE. We identified several dermatology quality of life instruments 
commonly used in CLE patients, but their validity and psychometric properties 
need to be further evaluated to determine whether they are appropriate to use in 
this population. Further studies are needed to better understand the impact of CLE 
from the patient’s perspective.
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OBJECTIVES: To assess the impact of shared decision making (SDM) for initiation 
of biologic therapy on future outcomes and healthcare utilization among patients 
with autoimmune conditions (rheumatoid and psoriatic arthritis, psoriasis, Crohn’s 
disease, ulcerative colitis, and anklyosing spondylitis). Patient characteristics were 
examined among an initial sample of 153 survey respondents. METHODS: Adult 
US health plan commercial enrollees with evidence of an autoimmune condition 
within the prior 6 months and an initial prescription for biologic treatment within 
the prior 2 months were identified in the Optum Research Database and mailed 
a survey in January 2014 (n= 265) and February 2014 (n= 147). Survey measures 
included the SDM Questionnaire (SDM-Q-9), general health status (GSRH), biologic 
treatment options discussed, as well as demographic and clinical characteristics. 
Quan-Charlson comorbidity scores were calculated using administrative claims 
data for the 6 months prior to biologic therapy initiation. Data were compared 
between respondents who participated in SDM and those who did not (non-SDM) 
based on SDM-Q-9 scores. RESULTS: A total of 145 surveys were analyzed (SDM: 
n= 53, non-SDM: n= 92). Respondents were primarily female (68%), Caucasian (91%), 
and 50 years old, on average. SDM respondents were more likely to be female (79% 
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OBJECTIVES: To assess the characteristics of SLE patients currently experiencing 
flares in Europe. METHODS: A multi-center retrospective medical chart review 
of adult (16-89 yrs) SLE patients was conducted in 1Q2014 among rheumatolo-
gists/internal medicine physicians in UK/France/Germany/Italy/Spain (5EU). 
Physicians were recruited from a geographically representative sample in each 
country. Approx. 5 consecutive eligible persistent active or relapse remitting SLE 
patients currently managed as part of usual care were identified within the study 
observation window. Physicians abstracted de-identified patient data on disease 
characteristics, lab values and treatment patterns. Patient disease status and 
humanistic burden was assessed by physician per clinical judgment & patient 
interaction. Patients experiencing a flare were identified for analysis. RESULTS: 
135 SLE patients who were experiencing flares were included in the analysis 
(UK:45/France:22/Germany:20/Italy:20/Spain:28). Mean age(yrs) was 5EU:40.6/
UK:44.4/France:39.3/Germany:36.9/Italy:41.0/Spain:37.9; % female was 5EU:78%/
UK:87%/France:59%/Germany:75%/Italy:70%/Spain:86%; % full-time employment 
was 5EU:33%/UK:20%/France:32%/Germany:30%/Italy:50%/Spain:43%; % part-time 
employment was 5EU:18%/UK:29%/France:9%/Germany:10%/Italy:10%/Spain:18%; 
% on sick leave was 5EU:17%/UK:9%/France:23%/Germany:25%/Italy:15%/
Spain:21%. Top-5 organ manifestations observed were musculoskeletal (5EU:88%/
UK:93%/France:100%/Germany:65%/Italy:95%/Spain:82%), mucocutaneous 
(5EU:85%/UK:96%/France:91%/Germany:65%/Italy:80%/Spain:82%), haematologic 
(5EU:56%/UK:56%/France:41%/Germany:60%/Italy:50%/Spain:68%), renal (5EU:33%/
UK:33%/France:23%/Germany:50%/Italy:45%/Spain:21%) and pulmonary (5EU:27%/
UK:38%/France:5%/Germany:10%/Italy:35%/Spain:32%). Percentage of patients 
with low C3 (5EU:73%/UK:55%/France:62%/Germany:85%/Italy:90%/Spain:89%), 
low C4 (5EU:78%/UK:59%/France:90%/Germany:90%/Italy:75%/Spain:89%) and 
positive anti-ds-DNA (5EU:90%/UK:80%/France:100%/Germany:95%/Italy:95%/
Spain:93%) were high. Among those with lab measures, mean ESR (mm/h) was 
5EU:50.1/UK:44.4/France:47.6/Germany:41.2/Italy:54.6/Spain:63.8; mean hemo-
globin (g/L) was 5EU:10.4/UK:9.8/France:11.1/Germany:10.5/Italy:10.5/Spain:10.7. 
Humanistic burden (reported via physician ratings, on a scale of 1 (most impact) 
to 7 (least impact)) was (mean scores): patient ability to perform every-day tasks 
- 5EU:4.4/UK:4.4/France:5.1/Germany:3.8/Italy:4.5/Spain:4.0; patient ability to 
interact fully with family and friends - 5EU:4.9/UK:4.9/France:5.5/Germany:4.2/
Italy:5.0/Spain:4.9; patient ability to work/keep employment - 5EU:3.9/UK:4.2/
France:4.2/Germany:2.8/Italy:4.2/Spain:3.7. Percentage of patients hospitalized 
> = 1 in the past-year was 5EU:56%/UK:40%/France:68%/Germany:65%/Italy:65%/
Spain:57%. CONCLUSIONS: SLE patients experiencing flares had significant clini-
cal and humanistic burden across the studied countries. Further scrutiny is war-
ranted to assess the modalities of care delivered to this patient group to alleviate 
their burden.
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OBJECTIVES: Orphan drugs are indicated for rare diseases and conditions. We 
assessed trends in approvals of new drugs with orphan indications in the US 
and in the prevalence of orphan drugs approved by the FDA from 1983 to 2014 
compared to non-orphan drug approvals in the same time frame METHODS: The 
study used regulatory and prevalence data derived from the US FDA, the European 
Medicines Agency (EMA), and other publicly available sources. Descriptive statis-
tics and the chi-square test were performed in the study. RESULTS: A total of 103 
BLAs and 799 NMEs were approved by the FDA from 1983 to 2014. The percentage 
of new drugs with orphan designation at approval was 43.7% for BLAs and 20.7% 
for NMEs (p< 0.001). Orphan drugs represented 13.9% of the new drugs approved 
from 1983 to 1989, 21.2% in the 1990s, 25.5% in the 2000s, and 33.8% from 2010 to 
2014. Information about the prevalence of disease was available for 73.7% of the 
orphan drugs. Indications approved for use in diseases with a prevalence of less 
than 1000 patients (i.e.: ultra-orphan drugs) represented 8.4% of all new orphan 
drugs. Ultra-orphan drugs represented 12.5%, 3.6%, 7.7%, and 15.8% of all orphan 
indications approved in the US from 1983-1989, 1990s, 2000s, and 2010-2014, 
respectively. CONCLUSIONS: This study found an increase in the percentage of 
drugs approved by the FDA for orphan diseases and conditions. Ultra orphan drugs 
revealed a greater increase over time than other orphan drugs as a proportion of 
all new drugs approved by the FDA. The limited innovation in diseases with large 
prevalence, the incentives provided by the Orphan Drug Act of 1982 and favorable 
reimbursement for orphan drugs in the US health care system may explain the 
increase in the approval of orphan drugs in the US.
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pain or bleeding completed a pain history and five PRO instruments (EQ-5D-5L, 
Brief Pain Inventory v2 [BPI], SF-36v2, International Physical Activity Questionnaire 
[IPAQ], and Hemophilia Activities List [HAL]) during routine clinic visits. To assess 
concordance of individual questionnaire items and correlation of domain/global 
scores using intraclass correlation coefficient (ICC), initial patients (target 125-150) 
were approached to complete the PROs at the end of their 3-4 hour visit in a simi-
lar non-bleeding state. RESULTS: From October 2013-October 2014, 381 patients 
enrolled; 164 (88% of initial 187) completed the retest. Median age of retest cohort 
was 33.9 years (Q1, Q3; 26.9, 46.0). Median time for completion of the initial survey 
with five PROs was 36.0 minutes and for the retest was 21.0 minutes. Median/mean 
time between tests was 1.5/1.6 hours. The majority of subjects had hemophilia 
A (74.4%) and were white-non-Hispanic (72.6%); 48.7% were married, 62.6% had 
some college or graduate-level education, 80.7% were employed, and 61.0% were 
overweight or obese. HCV was more common than HIV (49.4% vs 16.5%); 61.0% 
self-reported arthritis/bone/joint problems. Median/mean test-retest concord-
ance was: EQ-5D-5L, 80.0%/79.1%; BPI, 54.5%/58.9%; SF-36v2, 77.8%/76.4%; IPAQ, 
100%/100%; and HAL, 77.4%/75.9%. ICC for test-retest reliability were: EQ-5D-5L 
Health Index, 0.890; BPI–severity, 0.950; BPI–interference, 0.920; IPAQ total activity, 
0.940; SF-36v2 overall health, 0.910; HAL total score, 0.970. CONCLUSIONS: All five 
PROs are reliable in adult PWH. Therefore, the choice of instrument to be used for 
research or clinical care should be driven by instrument characteristics other than 
reliability.
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OBJECTIVES: Patient reported outcomes provide important information on the 
comprehensive impact of Systemic Lupus Erythematosus (SLE) on daily lives of 
patients. It also fosters patient physician communication, patient engagement and 
satisfaction with medical care. LupusPRO is a disease targeted patient reported 
outcome tool that has good measurement properties (Jolly et al., 2012) and has 
been validated in several countries. Herein we report the measurement properties 
of the Italian translation of the LupusPRO that was administered using a web based 
format. METHODS: LupusPRO was translated using forwards and back translation 
method into Italian language. It was pretested among 5 native Italian speaking 
subjects. As part of another study, 344 patients with SLE diagnoses were approached 
through the Patients organization network, asked to provide their demographics, 
medications and responses to the online LupusPRO. We evaluated internal consist-
ency reliability (ICR) of the LupusPRO domain items, floor-ceiling effects, known 
groups validity (KGV) and confirmatory factor analysis (CFA). ICR was tested using 
cronbach’s α . KGV was tested against current use of corticosteroids, with the hypoth-
esis that SLE patients currently on corticosteroids would have worse health status 
than without. Goodness of fit was evaluated in the CFA. RESULTS: Mean (SD) age 
and duration of disease were 39.7 (11.1) and 11.7 (9.3) yrs. Ninety one percent were 
women. Sixty four percent were on corticosteroids and sixty six percent were on 
hydroxychloroquine at the time of the study. ICR and Floor-ceiling effects were 
acceptable. The hypothesis about corticosteroids was supported for many subscales. 
On CFA, with few exceptions the items correlated highly (r> 0.5) with their hypoth-
esized scale. The CFI was 0.938 and TLI was 0.973 (> 0.9 is considered good model 
fit). The RMSEA was 0.093 (< 0.1 is considered acceptable model fit). CONCLUSIONS: 
Web version of LupusPRO Italian translation shows fair psychometric properties in 
Systemic Lupus Erythematosus patients.
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OBJECTIVES: Allogeneic hematopoietic stem cell transplantation (HSCT) can 
cure Sickle Cell Disease (SCD) but traditional chemotherapy-based conditioning 
regimens for HSCT are associated with substantial morbidity and mortality. The 
objective of this study was to determine if an innovative approach of chemo-
therapy-free, non-myeloablative HSCT with alemtuzumab is associated with 
improved health-related quality of life (HRQoL) in adult SCD patients. METHODS: 
Thirteen high-risk SCD patients underwent chemotherapy-free HSCT at a large 
urban academic medical center using human leukocyte antigen (HLA)-matched, 
related donors. Indications for transplantation in this cohort included frequent 
pain crises, stroke, and/or ≥ 2 lifetime episodes of acute chest syndrome. Generic 
HRQoL was assessed using the SF-36 in 9 patients who were assessed pre-HSCT 
and at 365 post-HSCT. Magnitude of effect was evaluated for SF-36 norm-based 
subscales and the SF-6D summary scores based on standardized response mean 
(SRM) (SRM> 0.5= medium; SRM> 0.8= large effect). RESULTS: Of 13 patients, all 
survived and 9 had completed 365 day post-HSCT assessments by time of analy-
sis. Mean change scores 365-day post-HSCT were 4.6 (SD 21.3) for physical func-
tioning (PF) (SRMPF= 0.2), 9.0 (SD 23.0) for role physical (RP) (SRMRP= 0.4), 17.1 
(SD 14.2) for bodily pain (BP) (SRMBP= 1.20), 18.6 (SD 16.0) for general health (GH) 
(SRMGH= 1.16), 15.2 (SD 10.5) for vitality (VT) (SRMVT= 1.45), 13.0 (SD 17.2) for social 
function (SF) (SRMSF= 0.76), 5.1 (SD 14.7) for role emotional (RE) (SRMRE= 0.34), 
5.7 (SD 9.8) for mental health (MH) (SRMMH= 0.59) and 0.21 (SD 0.13) forSF-6D 
index score (SRMSF6D= 1.66). CONCLUSIONS: Our pilot study demonstrated a 
large magnitude of improvement in HRQoL in terms of BP, GH, VT and overall 
health according to the SF-6D for SCD patients undergoing chemotherapy-free, 
non-myeloablative HSCT with alemtuzumab. These promising results, which are 
the first report of the impact of this innovative treatment on HRQoL in adults, war-
rant further investigation with more patients under treatment and longer-term 
follow-up.
